Pharming (PHAR) Depreciation & Amortization (CF) (2019 - 2025)

Pharming's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $11.2 million for Q4 2025.

• Quarterly Depreciation & Amortization (CF) fell 30.21% year-over-year to $11.2 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $11.2 million (down 40.38% YoY) and the FY2025 annual result came in at $11.2 million, changed N/A from the prior year.
• Depreciation & Amortization (CF) was $11.2 million for Q4 2025 at Pharming, down from $16.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $16.1 million in Q4 2024 and bottomed at -$4.4 million in Q3 2021.
• A 5-year average of $4.7 million and a median of $2.7 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Peak annual rise in Depreciation & Amortization (CF) reached 23680.7% in 2021, while the deepest fall reached 291.63% in 2021.
• Pharming's Depreciation & Amortization (CF) stood at $2.1 million in 2021, then advanced by 6.16% to $2.2 million in 2022, then surged by 244.98% to $7.6 million in 2023, then jumped by 112.71% to $16.1 million in 2024, then plunged by 30.21% to $11.2 million in 2025.
• Business Quant data shows PHAR's Depreciation & Amortization (CF) at $11.2 million in Q4 2025, $16.1 million in Q4 2024, and $2.7 million in Q3 2024.